Objective:To evaluate the efficacy of cervix ripening with vaginal controlled-release Propess. Patients and methods:A retrospective study of all women who underwent cervical ripening with Propess during the study peri...Objective:To evaluate the efficacy of cervix ripening with vaginal controlled-release Propess. Patients and methods:A retrospective study of all women who underwent cervical ripening with Propess during the study period from 1st January 2002 to 31st December 2004 was carried out. A total of 130 patients who experienced Propess was compared with the next following patient who delivered spontaneously matched on gestational age. Modes of delivery,failure of labor,maternal morbidity were recorded. Results:Indications for induction of labor were:post-term pregnancies in 18.5%,pre-eclampsia in 20.8%,oligohydroamnios in 18.5%,post-term pregnancy and oligohydramnios in 10.8%,intra-uterine fetal growth in 6.9%,premature rupture of membranes in 6.9%,diminution of fetal mobility in 6.1%and miscellaneous in 11.5%. Failure of cervical ripening was 21.2%. Patients in the Propess group had a 3.5 fold higher risk of Cesarean section 95%CI:1.5-8.3; P < 0.04 . There was no case of maternal or fetal death. There was no difference in incidence of maternal complications,and post-partum haemorrhage. Discussion and conclusion:Use of vaginal pessary Propess does not induce adverse maternal or fetal morbidity. However,it was associated with a higher incidence of Cesarean delivery.展开更多
目的:对比研究地诺前列酮与米索前列醇应用于促宫颈成熟的临床效果。方法:选取航空总医院2019年2月—2022年7月收治的足月妊娠且宫颈未成熟患者160例。应用随机数表法将其分成两组,各80例。地诺前列酮组应用地诺前列酮促宫颈成熟,米索...目的:对比研究地诺前列酮与米索前列醇应用于促宫颈成熟的临床效果。方法:选取航空总医院2019年2月—2022年7月收治的足月妊娠且宫颈未成熟患者160例。应用随机数表法将其分成两组,各80例。地诺前列酮组应用地诺前列酮促宫颈成熟,米索前列醇组应用米索前列醇促宫颈成熟,对比两组促宫颈成熟的效果、分娩方式、分娩结局及并发症发生情况。结果:治疗前,两组宫颈成熟评分比较,差异无统计学意义(P>0.05)。治疗后,两组宫颈成熟评分均高于治疗前,且地诺前列酮组高于米索前列醇组,差异有统计学意义(P<0.05)。地诺前列酮组自然分娩率为87.50%,高于米索前列醇组的71.25%,差异有统计学意义(P<0.05)。地诺前列酮组剖宫产率低于米索前列醇组,差异有统计学意义(P<0.05)。两组产后2 h出血量比较,差异无统计学意义(P>0.05)。地诺前列酮组总产程时间、用药至临产时间均短于米索前列醇组,新生儿5 min Apgar评分高于米索前列醇组,差异有统计学意义(P<0.05)。地诺前列酮组并发症总发生率为26.25%,高于米索前列醇组的23.75%,但组间比较差异无统计学意义(P>0.05)。结论:地诺前列酮与米索前列醇均可应用于促宫颈成熟,但相对来说地诺前列酮的临床效果更好,可促进自然分娩,减少剖宫产率,提高新生儿Apgar评分,减少产程时间,更加适合临床选择应用。展开更多
文摘Objective:To evaluate the efficacy of cervix ripening with vaginal controlled-release Propess. Patients and methods:A retrospective study of all women who underwent cervical ripening with Propess during the study period from 1st January 2002 to 31st December 2004 was carried out. A total of 130 patients who experienced Propess was compared with the next following patient who delivered spontaneously matched on gestational age. Modes of delivery,failure of labor,maternal morbidity were recorded. Results:Indications for induction of labor were:post-term pregnancies in 18.5%,pre-eclampsia in 20.8%,oligohydroamnios in 18.5%,post-term pregnancy and oligohydramnios in 10.8%,intra-uterine fetal growth in 6.9%,premature rupture of membranes in 6.9%,diminution of fetal mobility in 6.1%and miscellaneous in 11.5%. Failure of cervical ripening was 21.2%. Patients in the Propess group had a 3.5 fold higher risk of Cesarean section 95%CI:1.5-8.3; P < 0.04 . There was no case of maternal or fetal death. There was no difference in incidence of maternal complications,and post-partum haemorrhage. Discussion and conclusion:Use of vaginal pessary Propess does not induce adverse maternal or fetal morbidity. However,it was associated with a higher incidence of Cesarean delivery.
文摘目的:对比研究地诺前列酮与米索前列醇应用于促宫颈成熟的临床效果。方法:选取航空总医院2019年2月—2022年7月收治的足月妊娠且宫颈未成熟患者160例。应用随机数表法将其分成两组,各80例。地诺前列酮组应用地诺前列酮促宫颈成熟,米索前列醇组应用米索前列醇促宫颈成熟,对比两组促宫颈成熟的效果、分娩方式、分娩结局及并发症发生情况。结果:治疗前,两组宫颈成熟评分比较,差异无统计学意义(P>0.05)。治疗后,两组宫颈成熟评分均高于治疗前,且地诺前列酮组高于米索前列醇组,差异有统计学意义(P<0.05)。地诺前列酮组自然分娩率为87.50%,高于米索前列醇组的71.25%,差异有统计学意义(P<0.05)。地诺前列酮组剖宫产率低于米索前列醇组,差异有统计学意义(P<0.05)。两组产后2 h出血量比较,差异无统计学意义(P>0.05)。地诺前列酮组总产程时间、用药至临产时间均短于米索前列醇组,新生儿5 min Apgar评分高于米索前列醇组,差异有统计学意义(P<0.05)。地诺前列酮组并发症总发生率为26.25%,高于米索前列醇组的23.75%,但组间比较差异无统计学意义(P>0.05)。结论:地诺前列酮与米索前列醇均可应用于促宫颈成熟,但相对来说地诺前列酮的临床效果更好,可促进自然分娩,减少剖宫产率,提高新生儿Apgar评分,减少产程时间,更加适合临床选择应用。
